^
Association details:
| Biomarker: | BCL2L1 overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor) + navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2
Published date:
06/21/2020
Excerpt:
In addition, among the three cell lines, the combined effect of prexasertib and navitoclax resulted in increased apoptotic cell death because the protein expression levels of Bcl-xL and Chk1 were higher.
DOI:
10.1007/s11010-020-03796-6
